Skip to main content
Premium Trial:

Request an Annual Quote

Strong Consumables Sales Help Qiagen Post 20-Percent Revenue Gain in Q3

This article has been updated from a previous version, which incorrectly stated that 7 percent of Qiagen's third-quarter revenue came from Genaco Biomedical, instead of from acquisitions.
NEW YORK (GenomeWeb News) — Qiagen today said third-quarter revenues increased 20 percent as R&D spending rose 29 percent and profit increased 10 percent.
Total receipts for the three months ended Sept. 30 increased to $117.9 million from $98.6 million year over year, beating its guidance of $116 million.
The largest gains came from consumables sales, which conributed 20 percent to the growth. Around 7 percent of the quarter’s revenue came from acquisitions.
Sales in Asia also contributed to the company’s expansion as Qiagen saw a 63-percent increase in revenue in Asian markets.
R&D spending increased to $10.1 million from $7.8 million year over year.
The company said profit increased to $19.4 million from $17.6 million in the year-ago period.
Qiagen said it had around $492 million in cash and equivalents as of Sept. 30. 

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.